Celularity saw the highest growth of 1.99% in patent filings in April and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Celularity‘s patent filings and grants. Buy the databook here.
Celularity has been focused on protecting inventions in Israel(IL) with three publications in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 60% of grants. The China(CN), South Korea(KR), World Intellectual Property Organization(WIPO), and Israel(IL) patent Office are among the top ten patent offices where Celularity is filings its patents. Among the top granted patent authorities, Celularity has 60% of its grants in Israel(IL) and 20% in European Patent Office(EPO).
Pluri and Minovia Therapeutics could be the strongest competitors for Celularity
Patents related to rare diseases and cell & gene therapy lead Celularity's portfolio
Celularity has the highest number of patents in rare diseases followed by, cell & gene therapy. For rare diseases, nearly 100% of patents were filed and 40% of patents were granted in Q2 2024.
Ageing related patents lead Celularity portfolio followed by viral infections, and diabetic peripheral neuropathy
Celularity has highest number of patents in ageing followed by viral infections, diabetic peripheral neuropathy.
For comprehensive analysis of Celularity's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.